Tomoko Iehara

Tomoko Iehara

Auto-generated profile, based on publicly available information

Tomoko Iehara

Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2006 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
COCommittee of Neuroblastoma in the Japanese Society of Pediatric Oncology
Committee of Neuroblastoma in the Japanese Society of Pediatric Oncology
TIT Iehara
T Iehara
HHH Hosoi
H Hosoi
KAK Akazawa
K Akazawa
YMY Matsumoto
Y Matsumoto
TST Sawada
T Sawada
MYCN is the most powerful prognostic factor in cases of older children. However, how MYCN is related to the prognosis of infantile cases is not clear. A mass screening program was carried out by measuring urinary catecholamine metabolites (VMA and HVA) from 6-month-old infants. Of 2084 cases detected by the screening program, MYCN amplification (MNA) was examined by Southern blot analyses in 1533 cases from 1987 to 2000. Of the 1533 cases examined, 1500 (97.8%) showed no MNA, 20 cases (1.3%) showed MNA from three to nine copies, and 13 (0.8%) cases showed more than 10 copies. The 4-year overall survival rates of these three groups (99, 89 and 53%, respectively) were significantly different (P<0.001), indicating that MYCN copy number correlates with the prognosis. Cases with MNA more than 10 copies were more advanced than those without amplification (stage III, IV vs I, II, IVs; P<0.001). Patients with MNA more than 10 copies had significantly higher serum levels of neuron-specific-enolase (NSE) and ferritin than non-amplified patients (P=0.049, P=0.025, respectively). MYCN amplification was strongly correlated with a poor prognosis in infantile neuroblastoma cases. Therefore, for the selection of appropriate treatment, an accurate determination of MNA is indispensable.

26 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AMAtsushi Makimoto
Atsushi Makimoto
HFHiroyuki Fujisaki
Hiroyuki Fujisaki
KMKimikazu Matsumoto
Kimikazu Matsumoto
YTYoshiyuki Takahashi
Yoshiyuki Takahashi
YCYuko Cho
Yuko Cho
TITomoko Iehara
Tomoko Iehara
Retinoids are vitamin A derivatives and include trans-retinoic acid, isotretinoin, tamibarotene, and bexarotene, all of which are currently available for clinical use. The clinical development of retinoid therapy for neuroblastoma has a history spanning more than four decades. The most promising agent is isotretinoin, which can contribute to improving event-free survival in patients with high-risk neuroblastoma by approximately 10% when administered over six months as maintenance therapy. Although isotretinoin is regarded as an essential component in the standard clinical management of high-risk neuroblastoma, its use for this purpose in the US and EU is off-label. To promote isotretinoin use in Japan as a treatment for neuroblastoma, our clinical research team is planning to launch an investigator-initiated, registration-directed clinical trial. The present review article discusses the basic science behind retinoid therapy, pre-clinical/clinical evidence on neuroblastoma, the concept of the proposed clinical trial, and prospects for this therapy.

1 April 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YNYoshihiro Nitta
Yoshihiro Nitta
MMMitsuru Miyachi
Mitsuru Miyachi
ATAkimasa Tomida
Akimasa Tomida
YSYohei Sugimoto
Yohei Sugimoto
NNNorio Nakagawa
Norio Nakagawa
HHHajime Hosoi
Hajime Hosoi

12 August 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
ATAkimasa Tomida
Akimasa Tomida
SYShigeki Yagyu
Shigeki Yagyu
KNKayoko Nakamura
Kayoko Nakamura
HKHiroshi Kubo
Hiroshi Kubo
KYKumiko Yamashima
Kumiko Yamashima
TITomoko Iehara
Tomoko Iehara
Disialoganglioside (GD2)‐specific chimeric antigen receptor (CAR)‐T cells (GD2‐CAR‐T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. However, the effectiveness of immunotherapy using these cells is limited, and requires improvement. Combined therapy with CAR‐T cells and molecular targeted drugs could be a promising strategy to enhance the antitumor efficacy of CAR T cell immunotherapy. Here, we generated GD2‐CAR‐T cells through piggyBac transposon (PB)‐based gene transfer (PB‐GD2‐CAR‐T cells), and analyzed the combined effect of these cells and a MEK inhibitor in vitro and in vivo on neuroblastoma. Trametinib, a MEK inhibitor, ameliorated the killing efficacy of PB‐GD2‐CAR‐T cells in vitro, whereas a combined treatment of the two showed superior antitumor efficacy in a murine xenograft model compared to that of PB‐GD2‐CAR‐T cell monotherapy, regardless of the mutation status of the MAPK pathway in tumor cells. The results presented here provide new insights into the feasibility of combined treatment with CAR‐T cells and MEK inhibitors in patients with neuroblastoma.

2 March 2012 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TITomoko Iehara
Tomoko Iehara
JGJapanese Infantile Neuroblastoma Cooperative Study Group
Japanese Infantile Neuroblastoma Cooperative Study Group
MHMinoru Hamazaki
Minoru Hamazaki
TTTatsuro Tajiri
Tatsuro Tajiri
YKYoshifumi Kawano
Yoshifumi Kawano
TSTadashi Sawada
Tadashi Sawada

1 July 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TITomoko Iehara
Tomoko Iehara
SYShigeki Yagyu
Shigeki Yagyu
KTKunihiko Tsuchiya
Kunihiko Tsuchiya
YKYasumichi Kuwahara
Yasumichi Kuwahara
MMMitsuru Miyachi
Mitsuru Miyachi
HHHajime Hosoi
Hajime Hosoi
It remains unclear whether a residual tumor mass following therapy influences the prognosis of neuroblastoma. We retrospectively reviewed 20 patients with intermediate-risk tumors treated at our institution between 1993 and 2012 to elucidate whether additional treatment is required for residual tumors. The patient ages at diagnosis ranged from 0 days to 7 years. The 5-year overall survival rate was 94.4%. Thirteen patients had Stage 3 disease and seven patients had Stage 4 disease. Nine patients showed intraspinal extension. Twelve patients had a residual tumor mass at the completion of therapy, and eight showed intraspinal extension. Five of these 12 patients showed metaiodobenzylguanidine (MIBG) uptake at the end of treatment, but the uptake disappeared during the follow-up period. Except for one patient who died due to treatment complications, the rest are all alive, and nine are alive with a residual mass. We examined the residual mass in four patients and found that these tissues had differentiated into a ganglioneuroma or changed to a necrotic tissue. For the three patients with neurological symptoms at the end of treatment, some slight neurological symptoms still remained during the follow-up. Five patients with an intraspinal mass eventually presented with new symptoms. The presence of a residual mass at the end of treatment did not influence the patients’ prognosis. Therefore, an invasive radical surgical resection and additional treatment may not be necessary. Cases with a residual intraspinal mass also require a long-term follow-up to assess the neurological prognosis. The presence of a residual mass in cases of intermediate-risk neuroblastoma at the end of treatment did not influence the patients’ prognosis.